Thymosin alpha1 added to standard therapy improved 90-day transplant-free survival in 73 patients with HBV-related acute-on-chronic liver failure.
This open-label randomized controlled trial evaluated the efficacy of thymosin alpha1 added to standard medical therapy in patients with hepatitis B virus-related acute-on-chronic liver failure. The study population consisted of 73 patients, and the follow-up period was 90 days. Specific details regarding the setting and funding were not reported in the available data.
The primary analysis indicated that 90-day transplant-free survival was significantly increased with thymosin alpha1 treatment compared to standard medical therapy alone. Additionally, the treatment was associated with reduced frequencies of regulatory T cells and CD226 Treg subsets at weeks 4 to 8. The study also noted a moderated late-stage hyperinflammatory response in the intervention group.
Safety and tolerability data, including adverse events, serious adverse events, discontinuations, and specific tolerability metrics, were not reported in the abstract. Consequently, the safety profile remains unclear based on this evidence. The open-label design and small sample size of n=73 limit the generalizability of these findings.
Key limitations include the absence of reported effect sizes, p-values, or confidence intervals for the main outcomes. While the authors used causal language in conclusions, the results description does not explicitly support a definitive causal mechanism. Clinicians should interpret these findings with caution until larger, blinded trials confirm the magnitude of survival benefit and establish a robust safety profile.
View Original Abstract ↓
Immune Checkpoint Inhibitors Improve Survival and Response Rates in Patients with Hepatocellular Carcinoma Compared to Standard Therapy
New Drug Gives Liver Cancer Patients More Time
Related in Gastroenterology
From Other Specialties
